FishtownFish wrapped around the rod of AsclepiusMedicine
Philadelphia Primary Care
How It Works
What People Say
Patient reviews across 6 platforms
Articles
Symptoms
What your body is telling you
Treatments
Protocols, prescriptions, therapies
Longevity
Medicine 3.0 strategies
Heart Health & Risk
Protect your heart & vessels
Metabolism
Insulin, blood sugar, weight
Hormones
TRT, thyroid, menopause, andropause
Performance
VO2 max, muscle, sleep, gut
Playbooks
Step-by-step frameworks
About
Meet Dr. Ash
Your Physician
GERO·SPAN
Our Clinical Framework
FAQ
Common Questions
Book a Free Call
Ozempic vs. Metformin: Which Strategy Wins?
Fishtown Medicine•7 min read

Ozempic vs. Metformin: Which Strategy Wins?

On This Page
  • What Is the Difference Between Ozempic and Metformin?
  • Option 1: Metformin (The Foundation)
  • Who Is Metformin For?
  • How Does Metformin Help with Longevity?
  • Option 2: GLP-1 Medications (The Reset)
  • Who Are GLP-1 Medications For?
  • What Is the Main Risk?
  • What Is the Fishtown Strategy?
  • Guidance from the Clinic
  • Common Questions
  • Can you take metformin and Ozempic together?
  • Which is better for weight loss, Ozempic or metformin?
  • Is metformin safe long-term?
  • Are GLP-1 medications safe long-term?
  • Can metformin help with PCOS?
  • What is the typical metformin dose?
  • What about microdosing GLP-1s?
  • How quickly do these medications work?
  • Are there natural alternatives to metformin?
  • Who should avoid metformin?
  • Deep Questions
  • How does metformin affect mitochondrial function?
  • Can metformin really extend lifespan?
  • What is the SELECT trial and why does it matter?
  • How do GLP-1 medications affect the brain?
  • Why does metformin sometimes lower B12?
  • What is "Ozempic face" and how do you prevent it?
  • How does GLP-1 medication change blood pressure?
  • What is metabolic memory and how does it apply here?
  • Can these medications help with Alzheimer's risk?
  • Why do GLP-1 medications cause nausea?
  • What is muscle protein synthesis and why does it matter on GLP-1s?
  • How does the gut microbiome respond to metformin?
  • What is the difference between semaglutide and tirzepatide?
  • Can compounded semaglutide be trusted?
  • What is "GLP-1 plateau" and how do you handle it?
  • Why do these medications affect alcohol cravings?
  • Do these medications affect bone health?
  • How do you "exit" GLP-1 therapy safely?
  • Scientific References

Get a preventive doctor that knows you.

Consult Dr. Ash
TL;DR · 30-second take

Metformin is an inexpensive, well-studied insulin sensitizer that works by lowering liver glucose production. Ozempic (semaglutide) is a GLP-1 medication that quiets appetite and slows stomach emptying. Metformin is the foundation tool for early insulin resistance. Ozempic is for more entrenched metabolic dysfunction. We often use them together or in sequence.

Ozempic (Semaglutide) vs. Metformin: A Strategic Guide

TL;DR: Metformin is the Medicine 3.0 foundation: safe, cheap, and effective for early insulin resistance. Ozempic and Wegovy (GLP-1 medications) are stronger tools for entrenched metabolic dysfunction. We often use them together or in sequence to restore metabolic efficiency.

What Is the Difference Between Ozempic and Metformin?

Ozempic (semaglutide) and metformin are both metabolic medications, but they work in different ways. Metformin is an insulin sensitizer that lowers glucose production in the liver. Ozempic is a GLP-1 receptor agonist that slows stomach emptying, suppresses appetite, and improves insulin secretion.
FeatureMetforminOzempic / Wegovy (GLP-1)
MechanismSensitizes liver and muscle to insulinSlows digestion, suppresses appetite, improves insulin response
Metabolic impactFoundation tool for insulin sensitivityStrong neuro-hormonal reset
CostPennies per day$1000 or more per month without insurance
Longevity dataStrong (anti-aging research, possible cancer prevention)Strong cardiovascular protection (SELECT trial)
Side effectsGI upset (loose stools, nausea), B12 loweringNausea, vomiting, constipation, "Ozempic face"

Option 1: Metformin (The Foundation)

Metformin has been used for decades. It is derived from a compound first found in the French Lilac plant. It does not force the pancreas to pump more insulin. It cleans up by making the liver and muscle more sensitive to the insulin you already have.

Who Is Metformin For?

  • Anyone with fasting insulin above 5 to 7 micro-international units per milliliter
  • PCOS (polycystic ovary syndrome) patients
  • Patients interested in longevity and anti-aging support
  • Those wanting to prevent slow metabolic decline before diabetes shows up

How Does Metformin Help with Longevity?

Metformin activates AMPK (a cellular energy sensor that promotes repair) and inhibits mTOR (a growth pathway tied to aging). Population studies suggest metformin users have lower rates of certain cancers and slower cognitive decline. The TAME trial is currently testing whether metformin extends healthy lifespan in non-diabetic adults.

Option 2: GLP-1 Medications (The Reset)

GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound mimic a natural gut hormone called GLP-1. They slow stomach emptying, reduce hunger, and improve how the pancreas releases insulin in response to meals. They are powerful and should not be used casually.

Who Are GLP-1 Medications For?

  • Patients with significant metabolic dysfunction (insulin resistance, type 2 diabetes, PCOS)
  • Patients fighting strong baseline hunger drives
  • Those who have tried lifestyle plus metformin without enough progress
  • Patients with obesity-related conditions like sleep apnea or fatty liver

What Is the Main Risk?

The main risk of GLP-1 medications is muscle loss. Without protein and resistance training, 20% to 40% of weight lost may come from lean tissue. That can leave a patient looking thinner but worse off metabolically, a state called sarcopenic obesity (low muscle plus high body fat). We design plans to prevent this.

What Is the Fishtown Strategy?

We rarely start with GLP-1 medications unless the situation calls for it. Our typical approach has phases.
  1. Phase 1: Optimize protein, sleep, fiber, resistance training. Add metformin if insulin is rising.
  2. Phase 2: If labs and body composition stall, add a low-dose GLP-1 medication for 6 to 12 months.
  3. Phase 3: Taper the GLP-1 once labs and habits are stable. Maintain on metformin (if useful) plus lifestyle.
The goal is not to "stay on the shot forever" by default. The goal is to use the right tool for the right phase, and to have an exit strategy from day one.

Guidance from the Clinic

"Metformin is like the foundation of a house. GLP-1 medications are like the roof. You can have a house with both. Just do not skip the foundation and act surprised when the roof does not hold."
A common question I hear: "If GLP-1s work better, why bother with metformin?" My honest answer: metformin and GLP-1 medications do different jobs. Metformin sensitizes the liver and muscle. GLP-1 medications change appetite and gut signaling. Many of my patients do best on both, especially when fasting insulin is high but appetite control is also a problem. The pairing has stronger evidence than either alone in many studies.

Scientific References

  1. Holman RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-1589. Long-term metformin data.
  2. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
  3. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes. N Engl J Med. 2023;389(24):2221-2232. The SELECT trial.
  4. Aroda VR, et al. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program. J Clin Endocrinol Metab. 2016;101(4):1754-1761.
  5. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
Medical Disclaimer: This resource provides clinical context for educational purposes. In the world of Precision Medicine, there is no "one size fits all", the right metabolic medication choice must be matched to your unique lab work, physiology, and goals. Consult Dr. Ash to determine if this approach is right for you, especially if you have chronic health conditions or are taking prescription medications.

Frequently Asked Questions

Common Questions

Yes, you can take metformin and Ozempic together. The combination is common in type 2 diabetes care and is increasingly used in metabolic optimization. Each medication works through a different pathway, so they complement each other. Side effects sometimes overlap (GI upset), so dose timing matters.
Ozempic is generally better for weight loss than metformin. Metformin causes about 5 to 6 pounds of weight loss on average. Ozempic causes about 15% of body weight loss in non-diabetic patients in clinical trials, often 30 to 40 pounds for an average adult. The right choice depends on starting weight, labs, and goals.
Metformin is one of the most-studied medications in modern medicine and is generally very safe long-term. The main concerns are vitamin B12 lowering (we monitor and supplement) and very rare lactic acidosis (a serious blood acid imbalance, almost only in patients with severe kidney disease). Most patients tolerate metformin for decades.
GLP-1 medications appear safe long-term based on data going back over a decade for diabetes use. The SELECT trial confirmed cardiovascular safety and benefit in non-diabetic patients with prior heart disease. Rare risks include pancreatitis, gallbladder issues, and a possible rise in thyroid C-cell tumors (mostly seen in rodent studies). We screen for these.
Metformin is widely used for PCOS (polycystic ovary syndrome). It improves insulin sensitivity, often regulates menstrual cycles, lowers androgen levels modestly, and improves fertility in many women. It is usually first-line for PCOS in patients with insulin resistance.
The typical metformin dose for metabolic care is 500 mg to 2000 mg per day, usually starting at 500 mg with dinner and titrating up over 2 to 4 weeks to limit GI side effects. Extended-release versions are easier on the stomach. Some longevity-focused clinicians use 500 to 1500 mg in non-diabetic patients.
Microdosing GLP-1 medications means using doses below the FDA-approved range, often for metabolic optimization rather than significant weight loss. Some patients tolerate this better and avoid extreme appetite suppression. Long-term data is still emerging, so we use it selectively.
Metformin starts working within days, with full insulin-sensitizing effect around 2 to 4 weeks. Visible weight effects, when they happen, are gradual over 3 to 6 months. GLP-1 medications start working within days for appetite, with significant weight changes typically appearing by 8 to 12 weeks at therapeutic doses.
Berberine is sometimes called "nature's metformin." It activates similar pathways and has shown insulin-sensitizing effects in studies, though it is less potent and less proven than metformin. Cinnamon, chromium, and inositol have lighter evidence. Lifestyle interventions, especially resistance training, are the most powerful "natural" insulin sensitizers.
People who should avoid metformin include those with severe kidney disease (eGFR under 30 mL/min), severe liver disease, active heart failure, or significant alcohol use. People scheduled for procedures with IV contrast may need to pause it briefly. We review medical history before starting.

Deep-Dive Questions

Metformin partially inhibits Complex I in mitochondria (the energy-producing parts of cells), which paradoxically signals the cell to clean up and become more efficient. Some researchers worry about effects on muscle mitochondria during heavy training. Most evidence suggests modest doses (500 to 1500 mg per day) do not blunt training adaptations meaningfully in most patients.
Whether metformin extends lifespan in non-diabetic humans is being studied actively. Animal data shows lifespan extension in several species. Population studies of diabetic patients on metformin show lower rates of cancer and possibly Alzheimer's. The TAME trial aims to test this directly. We treat metformin as a "promising tool with low downside" rather than a proven longevity drug.
The SELECT trial published in 2023 showed that semaglutide (Wegovy) reduced major cardiovascular events by 20% in non-diabetic patients with overweight or obesity and prior heart disease. This was a major shift, because it proved that GLP-1 medications protect the heart even when given specifically for weight, not blood sugar. It changed how cardiologists think about obesity treatment.
GLP-1 medications act on receptors in the hypothalamus (the brain's hunger control center) and the reward system. They reduce "food noise," the constant intrusive thoughts about eating. Some studies suggest they may help with addictive behaviors beyond food, including alcohol and nicotine. Long-term effects on cognition are still being studied.
Metformin can lower vitamin B12 by interfering with calcium-dependent absorption in the gut. Long-term use raises the risk of B12 deficiency, especially in older adults and vegetarians. We test B12 yearly and supplement (typically 1000 mcg of methylcobalamin daily) when levels drop below 400 pg/mL.
"Ozempic face" describes the gaunt look that some people get from rapid weight loss on GLP-1 medications. Facial fat is lost along with body fat. Prevention focuses on slower loss, adequate protein, resistance training, and good hydration. Some patients address lost facial volume cosmetically once weight is stable.
GLP-1 medications often lower blood pressure modestly, by about 3 to 5 mmHg systolic. The mechanism includes weight loss, improved kidney sodium handling, and direct vascular effects. Patients on blood pressure medications sometimes need lower doses after starting GLP-1 medications, so monitoring is important.
Metabolic memory describes how early intensive control of blood sugar may protect against complications years later, even if control becomes less tight. The DCCT and EDIC trials in type 1 diabetes first showed this. Some clinicians believe similar logic applies to using metformin and GLP-1 medications early to "reset" trajectory rather than waiting for full-blown disease.
Some early data suggests GLP-1 medications may have neuroprotective effects, with trials underway in Alzheimer's disease. Metformin is also being studied for cognitive benefits. The mechanism likely involves reduced brain insulin resistance, lower inflammation, and improved cerebral blood flow. We do not yet recommend either drug specifically for dementia prevention, but the science is evolving.
GLP-1 medications cause nausea by slowing stomach emptying and acting on receptors in the brain that regulate nausea. Most patients adapt within 2 to 4 weeks at each dose level. We minimize nausea with slow titration, smaller meals, low-fat foods early on, and good hydration. Persistent severe nausea sometimes means the dose is too high too fast.
Muscle protein synthesis is how the body builds and maintains muscle. It is driven by protein intake and resistance training, especially the amino acid leucine. GLP-1 medications can lower appetite to a point where protein intake drops, slowing protein synthesis. Tracking protein at 1 gram per pound of ideal body weight and using whey or essential amino acid supplements helps protect muscle.
Metformin changes the gut microbiome. It increases bacteria like Akkermansia muciniphila (a strain linked to better metabolic health) and shifts the microbiome toward patterns seen in healthier people. Some of metformin's metabolic benefits may actually come from these microbiome changes, not just direct cellular effects.
Semaglutide (Ozempic, Wegovy) targets one receptor (GLP-1). Tirzepatide (Mounjaro, Zepbound) targets two receptors (GLP-1 and GIP). In the SURMOUNT-5 trial, tirzepatide produced about 20% body weight loss versus 14% for semaglutide. Side effects are similar. Tirzepatide tends to be slightly more expensive and was less available initially.
Compounded semaglutide became available because of FDA-approved drug shortages. Quality varies by pharmacy. We use compounded options only from licensed compounding pharmacies with strong quality controls and proper sterility. As name-brand supply has improved, the FDA has limited compounding eligibility for these drugs.
"GLP-1 plateau" is when weight loss stalls after several months on a GLP-1 medication. Causes include receptor desensitization, behavior drift, and metabolic adaptation. We sometimes increase the dose, switch agents (semaglutide to tirzepatide), add metformin, or accept the new set point and focus on body composition. Plateaus are normal, not failure.
GLP-1 medications appear to lower alcohol cravings in some patients. Receptors in the brain's reward system overlap between food and alcohol. Some early trials are testing GLP-1 medications specifically for alcohol use disorder. We do not prescribe them for that purpose yet, but we do see this effect in many patients.
Rapid weight loss from any cause (GLP-1, surgery, severe diet) can lower bone density. The mechanism likely involves reduced mechanical loading and possible direct effects on bone-forming cells. Resistance training, adequate calcium, vitamin D, and sometimes a DEXA scan to track bone help protect bone health during weight loss.
Exiting GLP-1 therapy involves a gradual taper, not abrupt stop, to reduce rebound hunger and weight regain. We usually drop one dose level every 1 to 2 months while watching for hunger return and weight changes. Staying on metformin, keeping resistance training, protein intake, and a maintained sleep routine all help hold the gains.

Still have a question?

He answers personally. Usually within a few hours.

Related Intelligence

Medical Weight Loss & Body Composition | Philadelphia

Medical Weight Loss & Body Composition | Philadelphia

A nuance-first approach to GLP-1s. We focus on body composition, not just the number on the scale, with HAES-aligned principles that prioritize health.

Read Deep Dive
Metabolic Health & Insulin Resistance Philadelphia | Longevity

Metabolic Health & Insulin Resistance Philadelphia | Longevity

Weight is a lagging indicator. Insulin is a leading indicator. We use fasting insulin, CGMs, and DEXA scans to find and fix metabolic dysfunction.

Read Deep Dive
Metabolic Reset & Better Biology | Philadelphia

Metabolic Reset & Better Biology | Philadelphia

A grounded clinical approach to metabolic health and GLP-1s. We focus on biological restoration and body composition, fixing the engine first.

Read Deep Dive

Talk it through with Dr. Ash.

If anything you read here raised a question, this is a free 20-minute Warm Invitation Call. Pick a time and we’ll work through it together.

HSA/FSA eligible
No initiation or cancellation fees
No copays

Loading scheduler...

Having trouble with the scheduler? Book directly on Dr. Ash’s calendar

FishtownFish wrapped around the rod of AsclepiusMedicine
Philadelphia Primary Care
2418 E York St, Philadelphia, PA 19125Home visits in Greater Philadelphia

Serving Fishtown · Art Museum · Bella Vista · Callowhill · Center City · Center City West · Chestnut Hill · East Kensington · Fairmount · Fitler Square · Graduate Hospital · Logan Square · Manayunk · Northern Liberties · Old City · Olde Richmond · Poplar · Port Richmond · Queen Village · Rittenhouse · Roxborough · Society Hill · Southwark

Explore by topic

Women’s Health
  • Perimenopause
  • Menopause 3.0
  • PCOS
  • Fertility
Men’s Health
  • TRT Therapy
  • TRT Safety
  • TRT vs Enclomiphene
  • Low Libido
Metabolic
  • Medical Weight Loss
  • Ozempic vs Metformin
  • Fasting Protocols
  • Visceral Fat
Cardiovascular
  • apoB & Heart Health
  • apoB vs LDL
  • Lp(a) Cholesterol
  • ED & Heart Risk
Longevity + Performance
  • Healthspan vs Lifespan
  • Biological Age
  • VO2 Max
  • Zone 2 Training
Supplements
  • Magnesium
  • Creatine
  • Omega-3
  • Foundational Stack

Content is for educational purposes only and does not constitute medical advice.

TermsPrivacyScope of PracticeClinical Independence